(19) SUOMI - FINLAND
(FI)

PATENTTI- JA REKISTERIHALLITUS
PATENT- OCH REGISTERSTYRELSEN
FINNISH PATENT AND REGISTRATION OFFICE

(10) **FI/EP3555070 T3**

(12) **EUROOPPAPATENTIN KÄÄNNÖS**
ÖVERSÄTTNING AV EUROPEISKT PATENT
TRANSLATION OF EUROPEAN PATENT SPECIFICATION

(45) Käännöksen kuulutuspäivä - Kungörelsedag av översättning - Translation available to the public **12.09.2023**

(97) Eurooppapatentin myöntämispäivä - Meddelandedatum för det europeiska patentet - Date of grant of European patent **09.08.2023**

(51) Kansainvälinen patenttiluokitus - Internationell patentklassificering - International patent classification
C07D 403/12 (2006 . 01)
C07D 403/14 (2006 . 01)
C07D 413/12 (2006 . 01)
C07D 471/04 (2006 . 01)
C07D 487/04 (2006 . 01)
C07D 491/04 (2006 . 01)
C07D 491/14 (2006 . 01)
C07D 498/04 (2006 . 01)
A61P 35/00 (2006 . 01)
A61K 31/519 (2006 . 01)

(96) Eurooppapatenttihakemus - Europeisk patentansökan - European patent application EP17829454.2

(22) Tekemispäivä - Ingivningsdag - Filing date **19.12.2017**

(97) Patenttihakemuksen julkiseksitulopäivä - Patentansökans publiceringsdag - Patent application available to the public **23.10.2019**

(86) Kansainvälinen hakemus - Internationell ansökan - International application **19.12.2017 PCT/US2017067192**

(30) Etuoikeus - Prioritet - Priority

19.12.2016 US US201662436139 P 09.06.2017 US US201762517840 P

(73) Haltija - Innehavare - Holder

1• Epizyme, Inc. , 400 Technology Square, 4th Floor , Cambridge, MA 02139 , (US)

(72) Keksijä - Uppfinnare - Inventor

1• CAMPBELL, John Emmerson , 30 Holworthy Place, No. 2 , Cambridge, MA 02138 , (US)
2• DUNCAN, Kenneth William , 105 Briar Lane , Westwood, Ma 02090 , (US)

(74) Asiamies - Ombud - Agent

Patentia Oy , Vakkatie 26c , 00430 Helsinki , (FI)

(54) Keksinnön nimitys - Uppfinningens benämning - Title of the invention

AMIINI-SUBSTITUOITUJA, HETEROSYKLISIÄ YHDISTEITÄ EHMT2:N ESTÄJINÄ JA NIIDEN KÄYTTÖMENETELMIÄ

AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF

PATENTTIVAATIMUKSET

1. Minkä tahansa kaavan (Ia')-(Ii') mukainen yhdiste:


(Ia'),

(Ib'),

(Ic'),

(Id'),

(Ie'),

(If'),

(Ig'),

(Ih'),

(Ii'),

tai sen tautomeeri tai yhdisteen tai tautomeerin farmaseuttisesti hyväksyttävä suola,:

jolloin

R^1 on H tai C_1-C_4-alkyyli;

kukin R^2, R^3, R^4 ja R^5 on valittu itsenäisesti ryhmästä, jonka nuodostavat: H, halogeeni, syaani, C_1-C_6-alkoksyyli, C_6-C_{10}-aryyli, OH, NR^aR^b, $C(O)NR^aR^b$, $NR^aC(O)R^b$, $C(O)OR^a$, $OC(O)R^a$, $OC(O)NR^aR^b$, $NR^aC(O)OR^b$, C_3-C_8-sykloalkyyli, 4-7-jäseninen heterosykloalkyyli, 5-6-jäseninen heteroaryyli, C_1-C_6-alkyyli, C_2-C_6-alkenyyli ja C_2-C_6-alkynyyli, jolloin C_6-C_{10}-aryyli, C_3-C_8-cykloalkyyli, 4-7-jäseninen heterosykloalkyyli, 5-6-jäseninen heteroaryyli, C_1-C_6-alkoksyyli, C_1-C_6-alkyyli, C_2-C_6-

alkenyyli ja C_2-C_6-alkynyyli ovat kukin valinnaisesti substituoitu yhdellä tai useammalla seuraavista halogeeni, OR^a, tai NR^aR^b, jossa kukin seuraavista R^a ja R^b on itsenäisesti H tai C_1-C_6-alkyyli;

R^6 on C_1-C_6-alkyyli, joka on valinnaisesti substituoitu yhdellä tai useammalla seuraavista: halogeeni, syaani, hydroksyyli tai C_1-C_6-alkoksyyli;

R^7 on $-Q^2$-T^2 , jossa Q^2 on sidos ja T^2 on 5-10-jäseninen heteroaryyli tai 4-12-jäseninen heterosykloalkyyli, jolloin 5-10-jäseninen heteroaryyli tai 4-12-jäseninen heterosykloalkyyli on valinnaisesti substituoitu yhdellä tai useammalla $-Q^3$ -T^3:lla, jolloin kukin Q^3 on itsenäisesti sidos tai C_1-C_3-alkyleenilinkkeri, jolloin kukin on valinnaisesti substituoitu yhdellä tai useammalla seuraavista halogeeni, syaani, hydroksyyli tai C_1-C_6-alkoksi, ja kukin T^3 on itsenäisesti valittu ryhmästä, jonka muodostavat H, halogeeni, syaani, C_1-C_6-alkyyli, C_2-C_6-alkenyyli, C_2-C_6-alkynyyli, C_3-C_8-sykloalkyyli, C_6-C_{10}-aryyli, 4-7-jäseninen heterosykloalkyyli, joka sisältää 1-4 heteroatomia valittuna joukosta N, O ja S, 5-6-jäseninen heteroaryyli, OR^f, $C(O)R^f$, $C(O)OR^f$, $OC(O)R^f$, $S(O)_2R^f$, NR^fR^g, $OC(O)NR^fR^g$, $NR^fC(O)OR^g$, $C(O)NR^fR^g$, ja $NR^fC(O)R^g$, jolloin kukin seuraavista R^f ja R^g on itsenäisesti H, C_3-C_8-sykloalkyyli tai C_1-C_6-alkyyli, joka on valinnaisesti substituoitu C_3-C_8-sykloalkyylilla, jossa C_3-C_8-sykloalkyyli, C_6-C_{10}-aryyli, 4-7-jäseninen heterosykloalkyyli tai 5-6-jäseninen heteroaryyli on valinnaisesti substituoitu yhdellä tai useammalla seuraavista halogeeni, syaani, hydroksyyli, C_1-C_6-alkyyli, C_2-C_6-alkenyyli, C_2-C_6-alkynyyli, tai C_1-C_6-alkoksiy tai $-Q^3$-T^3 on okso;

R^8 on H tai C_1-C_6-alkyyli;

R^9 is $-Q^4$-T^4, jossa Q^4 on sidos tai C_1-C_6-alkyleeni, C_2-C_6-alkenyleeni tai C_2-C_6-alkynyleenilinkkeri, joista kukin on valinnaisesti substituoitu yhdellä tai useammalla seuraavista halogeeni, syaani, hydroksyyli tai C_1-C_6-alkoksyyli, ja T^4 on H, halogeeni, OR^h, NR^hR^i, $NR^hC(O)R^i$, $C(O)NR^hR^i$, $C(O)R^h$, $C(O)OR^h$, $NR^hC(O)OR^i$, $OC(O)NR^hR^i$, $S(O)_2R^h$, $S(O)_2NR^hR^i$ tai R^{S2}, jossa kukin R^h ja R^i on itsenäisesti H tai C_1-C_6- alkyyli ja R^{S2} on C_3-C_8-sykloalkyyli,C_6-C_{10}-aryyli, 4-12-jäseninen heterosykloalkyyli, joka sisältää 1-4 heteroatomia valittuna joukosta N, O ja S, tai 5-10-jäseninen heteroaryyli, ja R^{S2} on valinnaisesti substituoitu yhdellä tai useammalla $-Q^5$-T^5:llä , jolloin kukin Q^5 on itsenäisesti sidos taiC_1-C_3-alkyleenilinkkeri, joista kukin on valinnaisesti substituoitu yhdellä tai useammalla seuraavista: halogeeni, syaani, hydroksyyli tai C_1-C_6-alkoksi, ja kukin T^5 on itsenäisesti valittu ryhmästä, jonka muodostavat H, halogeeni, syaani, C_1-C_6-alkyyli, C_2-C_6-alkenyyli, C_2-C_6-alkynyyli, C_3-C_8-sykloalkyyli, C_6-C_{10}-aryyli, 4-7-

jäseninen heterosykloalkyyli, joka sisältää 1-4 heteroatomia valittuna joukosta N, O ja S, 5-6-jäseninen heteroaryyli, OR^j, $C(O)R^j$, $C(O)OR^j$, $OC(O)R^j$, $S(O)_2R^j$, NR^jR^k, $OC(O)NR^jR^k$, $NR^jC(O)OR^k$, $C(O)NR^jR^k$, ja $NR^jC(O)R^k$, jolloin kukin seuraavista R^j ja R^k on itsenäisesti H tai C_1-C_6-alkyyli; tai $-Q^5$-T^5 on okso;

R^{14} on H, halogeeni, syaani, $P(O)R^lR^m$, C_1-C_6-alkyyli, C_2-C_6-alkenyyli, C_2-C_6-alkynyyli, C_3-C_{12}-sykloalkyyli, 4-7-jäseninen heterosykloalkyyli, 5-6-jäseninen heteroaryyli tai $-OR^6$, jolloin C_1-C_6-alkyyli, C_2-C_6-alkenyyli tai C_2-C_6-alkynyyli on valinnaisesti substituoitu yhdellä tai useammalla seuraavista halogeeni tai OR^6, ja kukin seuraavista R^l ja R^m on itsenäisesti C_1-C_6-alkyyli; ja

R^{15} on H, halogeeni, syaani tai $-OR^6$.

2. Patenttivaatimuksen 1 mukainen yhdiste, jolloin korkeintaan yksi ryhmistä R^3 ja R^5 ei ole H.

3. Jonkin edellisen patenttivaatimuksen mukainen yhdiste, jolloin ^{R3} on H tai halogeeni, jolloin edullisesti R^3 on H

4. Jonkin edellisistä patenttivaatimuksista mukainen yhdiste, jolloin
   a. R^5 on C_1-C_6-alkyyli; ja tai
   b. korkeintaan toinen seuraavista R^4 ja R^5 ei ole H; ja/tai
   c. vähintään yksi seuraavista R^4 ja R^5 ei ole H; ja/tai
   d. R^4 on H, C_1-C_6-alkyyli tai halogeeni; ja/tai
   e. korkeintaan toinen seuraavista R^2 ja R^5 ei ole H; ja/tai
   f. vähintään yksi seuraavista R^2 ja R^5 ei ole H; ja/tai
   g. R^2 on H, C_1-C_6-alkyyli tai halogeeni; ja/tai
   h. R^5 on C_1-C_6-alkyyli.

5. Jonkin edellisistä patenttivaatimuksista mukainen yhdiste, jolloin R^6 on substituoimaton C_1-C_6-alkyyli.

6. Jonkin edellisistä patenttivaatimuksista mukainen yhdiste, jolloin

a. T^2 on 4-12-jäseninen heterosykloalkyyli, joka sisältää 1-4 heteroatomia valittuna joukosta N, O ja S, joka on valinnaisesti substituoitu yhdellä tai useammalla -Q^3-T^3:lla ; tai

b. T^2 on 8-12-jäseninen bisyklinen heterosykloalkyyli, joka käsittää 5- tai 6-jäsenisen aryyli- tai heteroaryylirenkaan fuusioituneena ei-aromaattiseen renkaaseen; tai

c. T^2 on 8-12-jäseninen bisyklinen heterosykloalkyyli, joka käsittää 5- tai 6-jäsenisen aryyli- tai heteroaryylirenkaan fuusioituneena ei-aromaattiseen renkaaseen, jossa 5- tai 6-jäseninen aryyli- tai heteroaryylirengas on kytketty Q^2:een; tai

d. T^2 on 5-10-jäseninen heteroaryyli.

7. Jonkin edellisen patenttivaatimuksen mukainen yhdiste, jolloin

a. T^2 on valittu seuraavista  ,  ,  ,  ,  ,  , 



, ja näiden tautomeerit, joista kukin on valinnaisesti substituoitu yhdellä tai useammalla -Q^3-T^3:lla; tai

b. T^2 on valittu seuraavista 



, ja näiden tautomeerit, joista kukin on valinnaisesti substituoitu yhdellä tai useammalla Q^3-T^3:lla; tai

c. T^2 on valittu seuraavista  , ja näiden tautomeerit, joista kukin on valinnaisesti substituoitu yhdellä tai useammalla Q^3-T^3:lla.

8. Jonkin edellisistä patenttivaatimuksista mukainen yhdiste, jolloin

a. Q^3 on itsenäisesti sidos tai C_1-C_3-alkyleenilinkkeri, joista kukin on valinnaisesti substituoitu yhdellä tai useammalla seuraavista: halogeeni, syaani, hydroksyyli tai C_1-C_6-alkoksi, ja kukin T^3 on itsenäisesti valittu ryhmästä, jonka muodostavat H, C_1-C_6-alkyyli, C_3-C_8-sykloalkyyli, 4-7-jäseninen heterosykloalkyyli, OR^f, $C(O)R^f$, $C(O)OR^f$, NR^fR^g, $C(O)NR^fR^g$ ja $NR^fC(O)R^g$, missä C_3-C_8-sykloalkyyli tai 4-7-jäseninen heterosykloalkyyli on valinnaisesti substituoitu yhdellä tai useammalla halogeenilla, syaanilla, hydroksyylillä, C_1-C_6-alkyylla tai C_1-C_6-alkoksilla; tai

b. kukin Q^3 on itsenäisesti C_1-C_3-alkyleenilinkkeri, ja kukin T^3 on itsenäisesti NR^fR^g, jolloin kukin seuraavista R^f ja R^g on itsenäisesti H, C_3-C_8-sykloalkyyli tai C_1-C_6-alkyyli, valinnaisesti substituoitu C_3-C_8-sykloalkyylillä, missä C_3-C_8-sykloalkyyli, C_6-C_{10}-aryyli, 4-7-jäseninen heterosykloalkyyli tai 5-6-jäseninen heteroaryyli on valinnaisesti substituoitu yhdellä tai useammalla seuraavista halogeeni, syaani, hydroksyyli, C_1-C_6-alkyyli, C_2-C_6-alkenyyli, C_2-C_6-alkynyyli tai C_1-C_6-alkoksi.

9. Jonkin edellisistä patenttivaatimuksista mukainen yhdiste, jolloin

a. vähintään yksi seuraavista R^8 ja R^9 on H; tai

b. kukin seuraavista R^8 ja R^9 on H; tai

c. R^8 on H; tai

d. R^9 on $-Q^4$-T^4, missä Q^4 on sidos tai C_1-C_6-alkyleenilinkkeri, joka on valinnaisesti substituoitu yhdellä tai useammalla seuraavista halogeeni, syaani, hydroksyyli tai C_1-C_6-alkoksyyli, ja T^4 on H, halogeeni, OR^h, NR^hR^i, $NR^hC(O)R^i$, $C(O)NR^hR^i$, $C(O)R^h$, $C(O)OR^h$ tai R^{S2}, missä R^{S2} on C_3-C_8-sykloalkyyli tai 4-7-jäseninen heterosykloalkyyli, ja R^{S2} on valinnaisesti substituoitu yhdellä tai useammalla $-Q^5$-T^5:llä.

10. Jonkin edellisistä patenttivaatimuksista mukainen yhdiste, jolloin

(i) R^9 on C_1-C_3-alkyyli;

(ii) R^{14} on H, halogeeni tai C_1-C_6-alkyyli ja/tai

(iii) R^{14} on halogeeni tai $-OR^6$; ja/tai

(iv) R^{15} on H tai halogeeni; ja/tai

(v) R^{14} on halogeeni ja R^{15} on H; ja/tai

(vi) R^{14} on $-OR^6$ ja R^{15} on H; ja/tai

(vii) R^{14} on halogeeni ja R^{15} on halogeeni; ja/tai

(viii) R^{14} on $-OR^6$ ja R^{15} is halogeeni.

11. Jonkin edellisistä patenttivaatimuksista mukainen yhdiste, jolloin yhdiste on valittu seuraavassa taulukossa olevista yhdisteistä ja sen farmaseuttisesti hyväksyttävistä suoloista:

Yhdiste nro.	Rakenne
1	
2	
3	
4	
5	
6	

Yhdiste nro.	Rakenne
7	
8	
9	
10	
11	
12	

Yhdiste nro.	Rakenne
13	
14	
15	
16	
17	
18	

Yhdiste nro.	Rakenne
19	
20	
21	
22	
23	
24	

Yhdiste nro.	Rakenne
25	
26	
27	
28	
29	
30	

Yhdiste nro.	Rakenne
31	
32	
33	
34	
35	

Yhdiste nro.	Rakenne
36	
37	
38	
39	
40	
41	

Yhdiste nro.	Rakenne
42	
43	
45	
47	
48	
50	

Yhdiste nro.	Rakenne
54	
55	
56	
57	
58	
59	

Yhdiste nro.	Rakenne
60	
61	
62	
63	
64	
65	

Yhdiste nro.	Rakenne
66	
67	
68	
69	
70	
71	

Yhdiste nro.	Rakenne
72	
73	
74	
75	
76	
77	

Yhdiste nro.	Rakenne
78	
79	
80	
81	
82	

Yhdiste nro.	Rakenne
83	
84	
85	
86	
87	
88	

Yhdiste nro.	Rakenne
93	
94	
95	
96	
97	

Yhdiste nro.	Rakenne
98	
99	
100	
101	
102	

Yhdiste nro.	Rakenne
103	
104	
105	
106	
107	

Yhdiste nro.	Rakenne
108	
109	
110	
111	
112	

Yhdiste nro.	Rakenne
113	
114	
115	
117	
119	
121	

Yhdiste nro.	Rakenne
134	
135	
136	
137	
138	

Yhdiste nro.	Rakenne
139	
140	
141	
142	
143	

Yhdiste nro.	Rakenne
144	
145	
146	
147	
148	

Yhdiste nro.	Rakenne
149	
150	
151	
152	
153	

Yhdiste nro.	Rakenne
154	
155	
156	
157	
158	

Yhdiste nro.	Rakenne
159	
160	
161	
164	
165	

Yhdiste nro.	Rakenne
166	
169	
170	
171	
172	
173	

Yhdiste nro.	Rakenne
174	
175	
176	
177	
178	
181	
182	

Yhdiste nro.	Rakenne
185	
188	
191	
199	
200	

Yhdiste nro.	Rakenne
201	
204	
206	
207	
210	
212	

Yhdiste nro.	Rakenne
213	
218	
219	
220	
221	
222	

Yhdiste nro.	Rakenne
223	
224	
225	
226	
228	
229	

Yhdiste nro.	Rakenne
230	
232	
233	
234	
235	
237	

Yhdiste nro.	Rakenne
261	
285	
292	
293	

Yhdiste nro.	Rakenne
296	
306	
313	
317	
321	

Yhdiste nro.	Rakenne
323	
324	
331	
333	
334	

Yhdiste nro.	Rakenne
339	
340	
341	
342	

Yhdiste nro.	Rakenne
346	
348	
363	
364	
365	

Yhdiste nro.	Rakenne
368	
385	
386	

12. Farmaseuttinen koostumus sisältäen jonkin edellisistä patenttivaatimuksista mukaista yhdistettä ja farmaseuttisesti hyväksyttävää kantaja-ainetta.

13. Jonkin patenttivaatimuksista 1-11 mukainen yhdiste käytettäväksi lääkkeenä.

14. Jonkin patenttivaatimuksista 1-11 mukainen yhdiste käytettäväksi verihäiriön ehkäisyyn tai hoitoon estämällä metyylitransferaasientsyymiä, joka on valittuseuraavista EHMT1 ja EHMT2, jolloin edullisesti:

(i) verihäiriö on sirppisoluanemia tai β-talassemia; ja/tai

(ii) verihäiriö on hematologinen syöpä; ja/tai

(iii) syöpä on lymfooma, leukemia, melanooma, rintasyöpä, munasarjasyöpä, hepatosellulaarinen karsinooma, eturauhassyöpä, keuhkosyöpä, aivosyöpä tai hematologinen syöpä; ja/tai

(iv) hematologinen syöpä on akuutti myelooinen leukemia (AML) tai krooninen lymfaattinen leukemia (CLL); ja/tai

(v) lymfooma on diffuusi suurten B-solujen lymfooma, follikulaarinen lymfooma, Burkittin lymfooma tai non-Hodgkinin lymfooma; ja/tai

(vi) syöpä on krooninen myelooinen leukemia (CML), akuutti myelooinen leukemia, akuutti lymfosyyttinen leukemia tai sekalinjainen leukemia tai myelodysplastiset oireyhtymät (MDS).